# Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI

> **NCT04981041** · PHASE4 · UNKNOWN · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 2334 (estimated)

## Conditions studied

- Acute Coronary Syndrome
- Atrial Fibrillation

## Interventions

- **DRUG:** Prasugrel or Ticagrelor
- **DRUG:** Clopidogrel

## Key facts

- **NCT ID:** NCT04981041
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-16
- **Primary completion:** 2024-12-16
- **Final completion:** 2025-06-16
- **Target enrollment:** 2334 (ESTIMATED)
- **Last updated:** 2023-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04981041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04981041, "Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04981041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*